Indivior Leaps On Phase III Data For Depot Opioid Addiction Treatment

 
• By Alexandra Shimmings

Shares in UK company Indivior jumped by more than 12% on Aug. 17 on the LSE on the back of top-line Phase III data for its monthly buprenorphine depot for opioid addiction, and confirmation that a Q4 2017 US approval is still within its sights.

More from Clinical Trials

More from R&D